Viracta Therapeutics

84 articles with Viracta Therapeutics

• Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China

  8/23/2021

  Viracta  Therapeutics, Inc. today announced that it has reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in the People's Republic of China previously licensed to Shenzhen Salubris Pharmaceuticals Co., Ltd.

• Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors

  8/16/2021

  Viracta  Therapeutics, Inc. today announced the appointments of Flavia Borellini , Ph.D., and Jane F. Barlow , M.D., MPH, MBA, as independent members to Viracta's Board of Directors.

• Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

  8/12/2021

   Viracta Therapeutics, Inc. today announced financial results for the second quarter of 2021 and provided clinical and corporate updates.

• Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

  7/21/2021

  Viracta  Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Viracta's Investigational New Drug (IND) application to proceed into a Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV+ solid tumors.

• 

  FDA Gives OK for Viracta’s Phase Ib/II Trial of Oral Combo in Epstein-Barr Virus Tumors

  7/21/2021

  The study will also investigate the oral combination with PD-1 inhibitor pembrolizumab in EBV+ metastatic nasopharyngeal carcinoma (RM-NPC).

• Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team

  7/6/2021

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer.

• Viracta Therapeutics Announces its Addition to the Russell 2000® Index and other FTSE Russell Indexes

  6/28/2021

  Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that it has been added as a member of the small-cap Russell 2000® Index, the all-cap Russell 3000® Index, and the Russell Microcap® Index, effective upon the U.S. market open today, June 28, 2021, as part of the 2021 Russell indexes reconstitution.

• Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

  6/1/2021

  Now open for enrollment, NAVAL-1 is a multicenter basket trial with an adaptive Simon 2-stage design

• Viracta Therapeutics to Host Key Opinion Leader Webinar

  5/18/2021

  Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial Event to take place on Thursday, May 20th at 2:00 PM ET

• Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

  4/8/2021

  Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021

• Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

  3/11/2021

  Viracta  Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston , President and Chief Executive Officer of Viracta will present at the Oppenheimer 31 st Annual Healthcare Conference taking place virtually from March 16-18, 2021

• Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team

  3/4/2021

  Viracta  Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments of Drs. Stephen Rubino and Barry J. Simon to the Board of Directors

• Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference

  3/3/2021

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10 , 2021.

• Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

  2/16/2021

  Viracta  Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance

• Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

  12/7/2020

  Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas.

• Viracta Therapeutics to Present at the Solebury Trout Fall Private Company Showcase 2020

  10/8/2020

    Viracta  Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston , MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the Solebury Trout Fall Private Company Showcase on Thursday, October 15, 2020 at 1:00 pm ET

• Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD, FACP as Chairman of the Board of Directors

  9/14/2020

  Viracta Therapeutics, Inc. ("Viracta" or the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Roger J. Pomerantz, MD, FACP, as Chairman of its Board of Directors (the "Board")

• Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/9/2020

  Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference

• Viracta Announces the Appointment of Mark A. McCamish, MD, PhD as Strategic Advisor

  7/20/2020

  Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Mark A. McCamish , MD, PhD, has joined Viracta as a Strategic Advisor to the Company. Dr. McCamish will provide strategic, financial and operational guidance to the Viracta leadership team as the Com

• Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD to its Board of Directors

  7/14/2020

  Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz , MD, FACP, has been appointed to its Board of Directors. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect Corporation and brings